Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire N. Harrison*, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Ramon V. Tiu, Pierre Zachee, Eric Jourdan, Elliott Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)E317-E324
Number of pages8
JournalThe Lancet Haematology
Volume4
Issue number7
DOIs
Publication statusPublished - Jul 2017

Keywords

  • MYELOPROLIFERATIVE NEOPLASMS
  • AVAILABLE THERAPY
  • CLINICAL-TRIAL
  • MANAGEMENT
  • REVISION
  • JAK2

Cite this